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Evaluation of a two-centimeter lateral
surgical margin for excision of grade I and grade II
cutaneous mast cell tumors in dogs
Ryan P. Fulcher, DVM; Lori L. Ludwig, VMD, MS, DACVS; Philip J. Bergman, DVM, PhD, DACVIM;
Shelley J. Newman, DVM, DVSc, DACVP; Amelia M. Simpson, DVM, DACVS; Amiya K. Patnaik, DVM, MS†

Objective—To evaluate completeness of excision
and clinical outcome in dogs with cutaneous mast cell
tumors (MCTs) excised with a lateral margin of 2 cm
and a deep margin of 1 fascial plane.
Design—Prospective study.
Animals—16 client-owned dogs with 1 or more cutaneous MCTs.
Procedure—Excision of MCTs was performed with a
2-cm lateral margin and a deep margin of 1 fascial
plane. Histologic tumor grading was performed; surgical margins were categorized as complete or incomplete. Follow-up information was obtained via repeat
examination of the dogs by veterinarians or clientcompleted questionnaires.
Results—4 grade I and 19 grade II cutaneous MCTs
were evaluated. Overall, 21 (91%) MCTs were completely excised; 2 grade II tumors had foci of mast
cells at the 2-cm margin. Two dogs received adjunctive
treatments following surgery. Follow-up information
was available for all dogs (median follow-up period,
379 days; range, 51 to 538 days); no local recurrence
was detected during this time. De novo MCTs were
detected in 3 of 16 dogs at 37, 54, and 154 days after
surgery. Via Kaplan-Meier analysis, median survival
time and disease-free interval were both > 538 days
(medians not yet reached). No prognostic variables
were identified.
Conclusions and Clinical Relevance—Excision with a
2-cm lateral margin and a deep margin of 1 fascial
plane may result in satisfactory excision of grades I and
II MCTs in dogs, with recurrence rates similar to those
reported previously. Use of these margins may minimize complications associated with larger local tumor
resection. (J Am Vet Med Assoc 2006;228:210–215)

M

ast cell tumors are the most common cutaneous
neoplasm in dogs, comprising 7% to 21% of all
cutaneous tumors and 11% to 27% of all malignant
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cutaneous tumors in that species.1-3 Most MCTs develop
in older dogs (mean age, 8.5 years), and there is no
reported sex predilection.2 Most commonly, MCTs
develop in mixed-breed dogs; however, Boxers, Boston
Terriers, Labrador Retrievers, Beagles, and Schnauzers
are reported to be at high risk.1 At the time of diagnosis,
most dogs with cutaneous MCTs have a single mass;
however, multiple masses are detected in approximately 3% to 14% of cases1,4 and even in as many as 43% of
cases.5 Cutaneous MCTs are most often located on the
trunk of the body (48% to 58%) and on the limbs (25%
to 47%) but can develop anywhere on the skin.6-8
As many as 50% of cutaneous MCTs are considered malignant on the basis of their biological behavior.9 The metastatic rate of MCTs may be as high as
96% for undifferentiated tumors and < 10% for welldifferentiated tumors.1,10 Metastasis most commonly
involves regional lymph nodes, the spleen, and the
liver; less frequently, metastasis involves the lungs, kidneys, heart, and bone marrow.10
With regard to MCTs in dogs, many prognostic
factors have been identified, including age,4,11 breed,1
sex,8 stage7,12 and location of tumor,2,7,13 tumor size,8,14 the
interval between detection of tumor and surgery,8 plasma histamine concentration,15 presence of tumor-related systemic signs,16 evidence of metastasis at diagnosis,13 and recurrence;9 however, histologic grade of the
tumor appears to be the most important.17 Of all MCTs
in dogs, grade I tumors account for 34% to 38%, grade
II tumors account for 40% to 52%, and grade III
tumors account for 14% to 22%.4,17,18 However, there
may be discordance between histologic grades assigned
by different pathologists in as many as 50% of MCTs.5
Surgical excision remains the treatment of choice for
cutaneous MCTs. Because neoplastic cells often extend
beyond the observable or palpable tumor border,19,20
MCTs have been traditionally excised with a 3-cm margin
of tissue around the tumor and a deep margin of 1 fascial
plane.1 After MCT excision, local recurrence occurs in 0%
to 50% of dogs2,8,20,21 and distant recurrence or de novo
development occurs in 11% to 38% of dogs.6,11,20,21
Complete excision does not prohibit recurrence,17 and
completeness of excision may not affect local or distant
recurrence rates or outcomes.11,22 A recent study11 of grade
II MCTs treated with surgery alone revealed no significant
difference in local or distant recurrence rates between
completely excised and incompletely excised tumors, but
the number of dogs in that study was small.
Inclusion of a 3-cm lateral margin of unaffected tissue during excision of an MCT results in a large tissue
MCT

Mast cell tumor
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Materials and Methods
Sixteen client-owned animals were included in the study,
each with 1 or more cutaneous MCTs (diagnosed on the basis
of findings of cytologic examination of fine-needle aspirate
specimens of the mass or masses). For inclusion in the study,
dogs had to have ≥ 1 MCT located in an area of the body
amenable to tumor excision with a 2-cm lateral margin. In
some dogs, not all of the multiple MCTs could be excised
according to protocol; these dogs were included in the study,
but only those MCTs that were excised according to the investigational protocol were included in margin analysis. Dogs that
had undergone excision of an MCT at an anatomic location
separate from that of the present tumor were included, unless
they had received noncorticosteroid chemotherapy or radiation therapy at any time prior to excision of the present tumor.
Dogs were excluded from the study if they had non-MCT
malignancy concurrently or had had non-MCT malignancy
previously; had received chemotherapy (not including corticosteroids) for treatment of MCT or other malignancy at any
time; or at any time had surgical treatment or radiation therapy of an MCT at the site of the present tumor. Some dogs were
excluded because tumor locations (eg, scrotum or distal portion of an extremity) dictated that surgical margins would be
greater or less than those required by the investigational protocol. Informed consent was obtained from owners of all dogs.
All dogs were premedicated with a combination of
methadone (0.2 to 0.4 mg/kg [0.09 to 0.18 mg/lb], IM) and
either atropine sulfate (0.02 mg/kg [0.009 mg/lb], IM) or glycopyrrolate (0.01 mg/kg [0.005 mg/lb], IM). Some dogs also
received acepromazine (0.01 to 0.03 mg/kg [0.005 to 0.014
mg/lb], IM). Prior to induction of anesthesia, 1 dog was administered diphenhydramine (2 mg/kg [0.9 mg/lb], IM) alone and 1
dog was administered diphenhydramine (2 mg/kg, IM) and
cimetidine (5 mg/kg [2.3 mg/lb], IM). Agents for anesthetic
induction included diazepam (0.5 mg/kg [0.23 mg/lb], IV) in
combination with propofol (3 mg/kg [1.36 mg/lb], IV) or
thiopental (7 mg/kg [3.18 mg/lb], IV). Anesthesia was maintained with isoflurane (0.5% to 3%) delivered via an endotracheal tube; 1 dog also received a fentanyl infusion (0.03 to 0.06
µg/kg [0.014 to 0.027 µg/lb], IV). Cephazolin (22 mg/kg [10
mg/lb], IV) was administered perioperatively. Postoperatively,
dogs that remained hospitalized received methadone (0.2 to 0.4
mg/kg, IM) every 6 hours for the first 12 to 24 hours for pain
management. After discharge, most dogs were administered
butorphanol (0.15 to 0.32 mg/kg [0.068 to 0.145 mg/lb], PO)
JAVMA, Vol 228, No. 2, January 15, 2006

every 6 to 12 hours as needed for pain management; a transdermal fentanyl patch (approx 2 µg/kg/h) was applied to each of 3
dogs prior to discharge. Two dogs received carprofen (2.2 mg/kg
[1 mg/lb], PO, q 12 h) or deracoxib (3 mg/kg, PO, q 24 h) in
addition to opioid analgesics; 1 other dog was not administered
opioids or nonsteroidal anti-inflammatory drugs after discharge.
Each tumor site was prepared for surgery routinely. A
sterile surgical marker and ruler were used to delineate the
gross tumor margin and to mark the skin 1 and 2 cm from this
edge at 0o, 90o, 180o, and 270o around the tumor. These marks
at the 2-cm margin were then connected. The skin, subcutaneous tissue, and fascia were incised along this margin. The
fascia was held in its relative position at the skin edge with tissue forceps. The tumor was excised beneath the fascial plane
by use of sharp and blunt dissection techniques. Once the
tumor was removed, an additional biopsy specimen (approx
0.5 cm in length, width, and depth) of the deep tissue margin
was obtained (designated as the additional deep margin) to
ensure the ability to histologically evaluate the deep margin if
tumor cells abutted the fascia. New surgical gloves and instruments were used for closure of the surgical site. The surgical
margins were marked with surgical clips, and the incisions
were sutured closed. For each dog, all detectable MCTs were
removed during a single anesthetic episode.
Each excised MCT was prepared by use of a previously
described technique.20 Briefly, the cut surfaces were inked
with yellow dyea and were allowed to dry. The excised tumor
was then placed on a piece of cardboard and held in place
with several needles to maintain its original shape during fixation in neutral-buffered 10% formalin. The additional deep
margin was fixed in neutral-buffered 10% formalin.
Once fixation was complete, the tumor was sectioned by
use of modification of a previously described technique.20
Briefly, a 1-cm-long, full-thickness section of tissue was taken
at locations 0o, 45o, 90o, 135o, 180o, 225o, 270o, and 315o
around the 2-cm margin. Four similarly sized sections were
obtained from the 1-cm margin at the 0o, 90o, 180o, and 270o
positions. Two full-thickness sections were obtained from the
center of the tumor mass at right angles to each other to confirm the cytologic diagnosis and histologically assess the
margin deep to the tumor. Lastly, 1 section of the additional
deep margin was collected. All sections were stained with
H&E, and Giemsa stains were used when needed. All tissue
sections were evaluated histologically by 1 pathologist (SJN);
tumors were graded by use of the Patnaik grading system.17
All surgical margins were categorized as complete or incomplete, where incomplete resection was characterized as the
presence of mast cells within 1 mm of the surgical margin.
For each dog, follow-up information regarding tumor
recurrence or metastasis was obtained via repeat examination
by a veterinarian or through client communication. End points
for follow-up were local MCT recurrence, de novo MCT development, metastasis, and death. Local recurrence was defined
as development of an MCT at or within 2 cm of the original
surgical site. De novo development was defined as development of a cutaneous MCT at an anatomic location > 2 cm from
the original tumor. Metastasis was defined as evidence of MCT
in a noncutaneous tissue. Local recurrence, de novo development, and metastasis were confirmed via cytologic or histologic examination of tissue specimens, and any mass reported by
the owner that was not cytologically or histologically examined was categorized as an MCT for purposes of this study. The
disease-free interval was defined as the time from tumor excision to identification of local recurrence, de novo development, or metastasis. Survival time was defined as the time from
tumor excision to death due to any cause.
For each of the 16 dogs, data recorded and evaluated
included signalment; prior history of MCT, including treatment dates and histologic grade (if known); staging of the present tumor (if performed) and time of staging (either preoperScientific Reports: Original Study
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defect and may not be necessary for complete excision of
the tumor. In addition, the amount of tissue deep to the
tumor that must be removed for a complete excision is
not definitively known. Our group has previously investigated surgical margins required for excision of cutaneous MCTs in dogs; tumors were each excised with a
3-cm lateral margin, and the excised tissue was evaluated histologically at the 1-, 2- and 3-cm lateral margins.20
None of the specimens in that study20 had mast cells
detectable at the 2- or 3-cm lateral margin, suggesting
that a 2-cm lateral margin may be adequate for complete
excision of grade I and grade II MCTs. Tumor excisions
were performed with a deep margin of 1 fascial plane in
that study,20 and tumor cells were detected within 1 mm
of the deep margin of 2 of 20 grade II MCTs; however,
despite the location of tumor cells close to the deep margin, local recurrence did not occur in either of those 2
dogs. The purpose of the study reported here was to evaluate the completeness of excision and clinical outcome
in dogs with MCTs that were excised with a lateral margin of 2 cm and a deep margin of 1 fascial plane.
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atively or postoperatively); number of MCTs present; presence
of MCTs that were excised but not included in the study;
tumor size in 3 dimensions; tumor diameter (defined as the
largest dimension through the tumor); largest tumor diameter
for each dog (for dogs with > 1 MCT); tumor size score (the
sum of tumor measurements in the 3 dimensions); largest
tumor size score for each dog (for dogs with > 1 MCT); location of each tumor (defined as forelimb [distal to the scapulohumeral joint], hind limb [distal to the hip joint], trunk, or
head and neck); tumor location group for each dog (defined as
forelimb only, hind limb only, trunk only, or multiple locations); surgery date; histologic grade of the tumor or tumors;
highest histologic grade of tumor on each dog (for dogs with
> 1 MCT); detection of mast cells at the 1-cm, 2-cm, deep, and
additional deep margins; postoperative adjunctive treatments;
local MCT recurrence; de novo MCT development; metastasis;
disease-free interval; death; cause of death; and survival time.
Kaplan-Meier survival time and Kaplan-Meier diseasefree interval were calculated. For survival analysis, dogs were
censored as of the date they were last known to be alive or
the date they died as a result of other disease. For disease-free
interval analysis, dogs with no local MCT recurrence or de
novo MCT development were censored as of the date they
were last known to be disease-free.
Breed, sex, sexual intactness, MCT location group, highest histologic grade, and completeness of excision at the 2-cm
lateral margin were evaluated as potential prognostic variables
for the Kaplan-Meier disease-free interval via log-rank testing.
Cox proportional hazards analysis was used to evaluate age,
sex, weight, number of MCTs identified at the initial evaluation, number of MCTs included in the study, the largest tumor
size score, the largest tumor diameter, and tumor location
group as potential prognostic variables for the disease-free
interval. Statistical analyses were performed with a χ2 analysis
(categorical vs categorical), Kendall rank correlation (continuous vs continuous), Kruskal-Wallis test (categorical vs
continuous), and Mann-Whitney U test (categorical vs continuous) by use of a computer software package.b For all statistical tests, a value of P < 0.05 was considered significant.

Results
Sixteen dogs with 23 cutaneous MCTs met the criteria for inclusion in this study. The median age was 7 years
(mean, 6.9 years; range, 3 to 11 years). Nine dogs were
female (6 spayed and 3 sexually intact), and 7 dogs were
male (6 castrated and 1 sexually intact). Overall, 9 breeds
were represented: Pug (n = 4), American Pit Bull Terrier
(3), and mixed breed (3) were most common, and 6
other breeds had a single representative each. The mean
body weight was 25.1 kg (55.22 lb; median, 22.7 kg
[49.94 lb]; range, 5.9 to 62.3 kg [12.98 to 137.06 lb]).
One dog had a prior history of MCT. Previously,
this dog had 2 MCT excisions, each at different
anatomic locations; each of those tumors was a grade II
tumor, and each was completely excised. At the time of
inclusion of this dog in the study, there was no evidence of local recurrence at either excision site.
Ten of the 16 dogs had 1 cutaneous MCT at the initial evaluation. Six dogs had multiple MCTs: 4 dogs
each had 2 MCTs, 1 dog had 3 MCTs, and 1 dog had 4
MCTs. Fourteen of the 16 dogs had all of their MCTs
included in the study. Two dogs each had 1 additional
MCT that was excised but not included in the study. Of
these, 1 dog had 2 MCTs, of which 1 (a completely
excised grade I tumor) was excluded from the study
because the tissue was not processed according to the
investigational protocol. The other dog had 4 MCTs, 1
212
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of which (an incompletely excised grade II tumor) was
adjacent to another raised cutaneous mass that was
diagnosed cytologically as an MCT but was diagnosed
via histologic evaluation as a focal acute hematoma;
these 2 masses were excised together with a single elliptical incision that did not follow the study protocol.
Staging procedures varied among dogs. Preoperative staging procedures were performed in 9 of the 16
dogs and included thoracic radiography (n = 6);
abdominal ultrasonography (6); cytologic evaluation
of a bone marrow aspirate (4); abdominal radiography
(4); assessment of a buffy coat smear (3); and cytologic evaluation of fine-needle aspiration specimens of the
regional lymph node (2), liver (1), and spleen (1).
Four of 16 dogs (including 1 dog with preoperative
staging) had staging procedures performed postoperatively, including abdominal ultrasonography (n = 2),
cytologic evaluation of a bone marrow aspirate (1),
thoracic radiography (1), assessment of a buffy coat
smear (1), and cytologic evaluation of fine-needle aspirates of the liver (1) and spleen (1). Mastocytosis or
metastasis was not evident in any dog in which staging
procedures had been performed, regardless of whether
assessments were made pre- or postoperatively.
The 23 MCTs were located on the trunk of the
body (n = 10 [44%]), hind limb (7 [30%]), forelimb (3
[13%]), and head and neck (3 [13%]). Of the MCTs on
the extremities, all were proximal to the tarsus on the
hind limb or proximal to the elbow joint on the forelimb. Considering every tumor on a given dog, 6 dogs
had MCTs on the trunk of the body only, 5 had MCTs
on the hind limb only, and 5 had MCTs in multiple
location categories; no dog had MCTs exclusively on
the forelimb. Mean tumor diameter was 1.3 cm (median, 1.1 cm; range, 0.4 to 3.1 cm). The mean largest
tumor diameter for each dog was 1.5 cm (median, 1.15
cm; range, 0.4 to 3.1 cm). The mean tumor size score
was 3.3 cm (median, 2.8 cm; range, 1.0 to 8.8 cm). The
mean largest tumor size score for each dog was 3.8 cm
(median, 3.25 cm; range, 1.0 to 8.8 cm).
Four of the 23 (17%) MCTs were grade I tumors,
and 19 (83%) were grade II tumors. There were no grade
III tumors. Overall, 21 of the 23 (91%) MCTs were completely excised. All grade I tumors were completely
excised at the 1- and 2-cm margin. For 13 of the 19
grade II MCTs, no mast cells were detected at the 1-cm
margin; for 17 of those 19 tumors, no mast cells were
detected at the 2-cm margin. All tumors were completely excised at the deep margin, and in all instances, the
additional deep margin was devoid of mast cells.
In 2 grade II tumors from 2 dogs, excisions were
deemed incomplete because of the presence of mast cells
at the 2-cm margin. There was a perivascular infiltrate
comprised of eosinophils and occasional well-granulated
mast cells and lymphocytes in 1 of the eight 2-cm marginal sections and 2 of the four 1-cm marginal sections
obtained from 1 of those 2 tumors; however, there was no
apparent connection between these foci and the primary
mass. The dog from which this tumor had been excised
had no additional treatments performed, and there was
no evidence of local MCT recurrence or de novo MCT
development during a follow-up period of 375 days. The
second incomplete MCT excision had a small focus of
JAVMA, Vol 228, No. 2, January 15, 2006

Discussion
The median age (7 years) and sex distribution
(approx 1.3 females to 1 male) of the dogs in the present study were similar to groups used in prior studies.4,6,11,14,20 The American Pit Bull Terrier appears to be
overrepresented in our study; however, the proportion
of this breed in the population of dogs evaluated at The
Animal Medical Center is unknown and may indeed be
higher than other previously reported populations.
Of the 16 dogs, 6 (38%) had more than 1 cutaneous
MCT. This proportion is considerably higher than the 3%
to 14% described in most reports1,4 and higher than findings in 2 previous studies17,20 from our institution (ie,
among dogs with MCTs, 0% and 10% had multiple MCTs
at initial evaluation, respectively). However, in another
JAVMA, Vol 228, No. 2, January 15, 2006

study5 of dogs with MCTs, 6 of 14 (43%) dogs had multiple MCTs. It is unknown whether dogs with multiple
MCTs are at higher risk for local recurrence or de novo
MCT development; however, no variables were identified
as prognostic for a disease-free interval in our study.
Tumors were located on the trunk, extremities,
head, and neck. Undoubtedly, the selection criteria
used in the present study affected the distribution of
tumor locations because tumors in certain anatomic
locations (eg, the scrotum or distal portions of the
extremities) were excluded. Given that the tumor location may be prognostic for the biologic behavior of
MCTs, there may be an effect on outcome as a result of
the exclusion of certain sites, such as distal portions of
the extremities and the muzzle.7,13
The mean tumor diameter (1.3 cm) among tumors
in the present study was smaller than that determined
in other studies,4,6,21 in which the mean value was
approximately 2.0 cm. The mean tumor size score was
3.3 cm, which was also smaller than a previously
reported value.20 This difference may be a consequence
of the small sample size of this study and our prior
study. Perhaps earlier detection of MCTs by owners
(who are generally becoming increasingly aware of
their pets’ overall health) may have contributed to the
apparent trend in the literature toward smaller tumor
size at diagnosis. Whether the smaller tumor size
among the dogs in our study influenced the clinical
outcomes is unknown. However, tumor diameter and
tumor size score were neither related to completeness
of excision nor prognostic for disease-free interval.
Overall, 21 of the 23 (91%) MCTs in the dogs of the
present study were completely excised. This proportion
compares well with the finding of another study,6 in
which 54 of 60 (90%) MCT excisions were complete, 3
(5%) were complete but close (ie, neoplastic cells were
detected within 1 mm of the margin), 1 (2%) was incomplete (ie, neoplastic cells were detected at the margin),
and the classification of 2 (3%) was unknown following
surgery. However, in that study,6 21 of the 60 (35%)
tumors had incomplete excisions prior to definitive surgical treatment, indicating that the rate of complete excision
following initial surgical treatment may be as low as 65%.
In our prior investigation of surgical margins associated
with MCTs,20 all 23 tumors were excised completely at the
3-cm lateral margin. However, the excisions of 2 (9%)
tumors were considered complete but close on their deep
margin (ie, neoplastic cells present within 1 mm of the
surgical margin). A report23 that included descriptions of
the completeness of surgical margins of 214 cutaneous
MCTs in dogs that were treated with excisional surgery
indicated that only 42% had complete margins, 19% had
narrow margins (ie, neoplastic cells within 5 mm of the
margin), and 39% had incomplete margins (ie, neoplastic
cells at the margin). In this light, complete excision of
91% of the MCTs in the present study seems acceptable.
Two of the 23 (9%) excisions were categorized as
incomplete because there were foci of mast cells at the 2cm margin. Previous investigations20,24,25 in dogs revealed
clumps of mast cells within grossly normal marginal tissues surrounding cutaneous MCTs. In the present study,
the relationship between the mast cells at a marginal section and the resected tumor is unknown. Although these
Scientific Reports: Original Study
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well-granulated mast cells and eosinophils in the subcutis in 1 of the eight 2-cm marginal sections and all of
the 1-cm marginal sections. The dog from which this
tumor had been excised had a second surgery performed
2 weeks after the excision to remove a 2-cm margin
around the initial surgical site. There was no evidence of
gross disease in this dog at the time of the second surgery,
and histologic evaluation of the excised tissue revealed
no evidence of MCTs. This dog also had no evidence of
local recurrence or de novo MCT development during a
follow-up period of 433 days.
One dog received adjunctive chemotherapy (consisting of administration of prednisone, vinblastine,
and cyclophosphamide) after surgery. The dog had an
incomplete resection of a grade II MCT that was not
included in the study because it was adjacent to another raised cutaneous mass (diagnosed cytologically as
an MCT but histologically as an acute focal hematoma)
and could not be excised according to the investigational protocol (the masses were excised together with
a single elliptical incision). Within a follow-up period
of 224 days, there was no evidence of local recurrence
or de novo MCT development in this dog.
The median follow-up interval for all dogs was 379
days (range, 51 to 538 days). None of the dogs had
local recurrence of an MCT. De novo MCTs developed
in 3 of the 16 dogs (a mixed-breed dog, a Viszla, and
an American Pit Bull Terrier); these tumors were
detected after disease-free intervals of 37, 54, and 154
days. All de novo tumors developed in dogs with complete excisions of grade II MCTs, and all de novo
tumors were histologically classified as grade II. At the
initial study evaluation, 2 of these dogs had multiple
MCTs; 1 of these dogs had a history of 2 MCT excisions (each a grade II tumor) at 5 months and 4 years
prior to inclusion in our study. Treatment for these de
novo tumors included complete surgical excision in 2
dogs and cytoreductive surgery combined with fullcourse radiation therapy in another dog.
The Kaplan-Meier median disease-free interval
was > 538 days (median not yet reached); 13 of 16
dogs were estimated to remain disease-free at 538 days.
Dogs were either disease-free at the time of last followup or had de novo MCT development. No prognostic
variables for the disease-free interval were identified.
Kaplan-Meier medial survival time was > 538 days; all
dogs were alive at the end of the study period.
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cells were assumed to be neoplastic for the purposes of
our analyses, their true nature is unknown, as standard
light microscopy alone cannot determine the neoplastic
potential of such cells. Other techniques, such as
immunohistochemistry,4,12,18,26 morphometry,5 and biochemistry,25 may be used to elucidate the nature of these
cells or may help identify neoplastic cells at the excisional margin that could have otherwise gone unnoticed.27
Of the 2 dogs with an incomplete MCT excision in
our study, 1 underwent a second excisional procedure,
in which a 2-cm margin of tissue was excised around
the scar from the initial surgery. Evidence of gross or
microscopic disease was not detected in the resected
tissue, as has been reported on other occasions.23 This
finding brings into question whether the initial surgery
was truly an incomplete resection and further supports
the idea that the foci of mast cells detected histologically may not have been associated with the primary
tumor. In 433 days and 375 days, respectively, since the
surgery, there had been no local recurrence of MCT in
this dog or in the other dog with an incomplete tumor
excision that received no additional treatment.
The preparation of tissue specimens, sectioning
methods, and margin examinations used in our study
presumably differed from routine preparation and
analysis performed in most commercial laboratories.
Although the present study involved extensive measures to maintain the relationship of the tissues from
skin to fascia, demarcate the surgical margin with tissue
dye, and exhaustively evaluate the surgical margins,
such practices are not standard, even at our institution.
Because different tissue fixation and sectioning techniques could alter margin assessment, careful consideration should be applied to the interpretation of margin
results obtained from standard sample processing.
The additional deep margin was evaluated in our
study because of our previous experience20 involving
detection of a complete but close, deep margin associated with excision of an MCT. However, in the present
study, no MCTs extended to the deep fascial layer, so
evaluation of this additional deep margin appears to
have been unnecessary. Although it seems unlikely that
tumor cells would cross a fascial plane, findings of the
present study cannot confirm this claim.
De novo development of an MCT was detected in 3
of the 16 dogs at 37, 54, and 154 days after surgery. This
finding compares well with those of earlier studies6,11 in
which, following tumor excision alone, development of
an MCT in a different cutaneous location occurs in 11%
to 38% of dogs. The de novo development of MCTs in
the dogs of the present study occurred earlier than it did
in dogs of our other study20 (mean interval after surgery
to detection of de novo MCTs, 386 days) and earlier
than it did in dogs of studies6,21 by other investigators (in
which the interval after surgery to detection of a de novo
MCT at a different body location ranged from 240 days
to 18.5 months). It is unknown why de novo development of MCTs was detected earlier in the present study,
and a lack of standardized staging procedures among
these studies makes it difficult to comment on potential
differences between the study populations.
The absence of grade III MCTs in the dogs of our
study makes application of the results to all types of
214
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MCTs in dogs impossible. Whether grade III tumors
could have met the inclusion criteria for our study is
unknown, as many develop in anatomic locations that
are not amenable to wide excision1,2,7,13; also, the extent of
invasion of grade III MCTs into adjacent tissues is largely unknown, making concise definition of wide surgical
margins impossible at this time. Further studies are needed to determine how far neoplastic cells extend from the
gross tumor margin in grade III MCTs; presumably, margin recommendations for grade III MCTs may be different than those for the other tumor grades. If surgical recommendations vary in accordance with histologic grade,
preoperative grade assessment may become necessary,
either through histologic means or perhaps through cytologic or immunocytologic methods.28
Terminology describing outcome analysis of MCT
excision is not standardized in the veterinary literature.
There is some consensus regarding the use of the term
local recurrence. However, descriptions of tumors that
develop subsequently at sites other than the original
location vary and include terms such as de novo development, distant recurrence, and metastasis.6,11,21
Similarly, the disease-free interval has been used in several ways in the literature.6,20,21 These differences highlight the difficulty regarding assessment of prognosis,
determination of etiopathogenesis, and prediction of
development of MCTs in dogs. Further standardization
of the terminology used to describe clinical outcomes
and study of the relationship between 1 MCT and another in a given dog will be necessary to decrease these difficulties. Perhaps immunocytologic and genetic evaluations of MCTs29 will provide data with which to elucidate
the relationships among MCTs in a dog with multiple
lesions and between a resected MCT and its recurrence.
In dogs of the present study, excision of cutaneous
MCTs with a 2-cm lateral margin and deep margin of 1
fascial plane resulted in complete excision in 91% of
grades I and II MCTs. Although mast cells detected at
the surgical margins in the incomplete MCT excisions
were assumed to be part of the neoplastic process, it is
unknown whether those cells reflect a true neoplastic
process or focus. In the dogs of our study, excision of
tumors with margins set by our investigational protocol
resulted in a local recurrence rate and de novo development rate that compared well with prior reports.
Alhough the case number was small, our data suggest
that excision of MCTs at these investigational margins
results in similar clinical outcomes in dogs with wider
excisions. However, extrapolation of these results to
grade III MCTs and MCTs on the muzzle, scrotum, or
distal portions of the extremities in dogs is difficult.
Further investigation into the surgical margins required
for complete excision of grade III MCTs is warranted.
a.
b.
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Correction: In “Evaluation of five commercially available assays and measurement of
serum total protein concentration via refractometry for the diagnosis of failure of passive transfer of immunity in foals,” published November 15, 2005 (J Am Vet Med Assoc
2005;227:1640–1645), the comparisons in Table 6 were incorrect. The table with the
corrected comparisons is reprinted below.

Table 6Summary statistics (mg/dL) of the differences between
the reference method* and a handheld quantitative colorimetric
immunoassayh (assay H) or the difference between 2 radial
immunodiffusiona,b assays (assays A and B) at serum IgG concentrations  400 mg/dL, 400 to 800 mg/dL, and  800 mg/dL.
Comparisons
Reference method
− assay H
Assay B – assay A

IgG
(mg/dL)

Mean bias
( SD)

Limits of
agreements

 400

46.7  97a

400–800
 800
 400
400–800
 800

256  233
385  378b
72.7  91.2a
−136.7  239b
−61.5  748b

−143 to 237
b

−199 to 712
−354 to 1,126
−101 to 251
−605 to 332
−1,528 to 1,405

For each sample, the average of IgG concentrations obtained
from the 2 radial immunodiffusion assaysa,b (assays A and B) was
used as the reference method to which the other assay results
were compared.
a,b
Within a comparison, mean bias values with different superscript letters are significantly (P  0.01) different.
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